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Currently, there are no effective treatments to directly repair damaged heart tissue after
cardiac injury since existing therapies focus on rescuing or preserving reversibly damaged
tissue. Cell-based therapies using cardiomyocytes generated from stem cells present
a promising therapeutic approach to directly replace damaged myocardium with new
healthy tissue. However, the molecular mechanisms underlying the commitment of stem
cells into cardiomyocytes are not fully understood and will be critical to guide this new
technology into the clinic. Since GATA4 is a critical regulator of cardiac differentiation, we
examined the molecular basis underlying the early activation of GATA4 gene expression
during cardiac differentiation of pluripotent stem cells. Our studies demonstrate the direct
involvement of histone acetylation and transcriptional coactivator p300 in the regulation
of GATA4 gene expression. More importantly, we show that histone acetyltransferase
(HAT) activity is important for GATA4 gene expression with the use of curcumin, a HAT
inhibitor. In addition, the widely used histone deacetylase inhibitor valproic acid enhances
both histone acetylation and cardiac specification.
Keywords: GATA4, gene regulation, histone acetylation, cardiac differentiation, cardiomyocytes
INTRODUCTION
Cardiovascular diseases are among the leading causes of death
for men and women worldwide with end stage heart failure
being the primary cause of mortality and morbidity (Go et al.,
2013). Most survivors of cardiac damage live with inadequate
heart function which reflects the limited ability of human car-
diac cells to proliferate and replace injuredmyocardium. For these
patients, treatment withmulti or pluripotent stem cells represents
a promising renewable therapy since these cells can be generally
programmed to replace damaged tissue. Thus, elucidating the
molecular mechanisms underlying gene cascades to commit the
stem cells into a cardiac fate is essential for developing the best
strategies to direct cardiac differentiation.
The initiation of cardiac differentiation is indicated by the
expression of the early cardiac genes, which include GATA bind-
ing protein 4 (GATA4), myocyte enhancer factor 2C (MEF2C)
and NK2 transcription factor related locus 5 (Nkx2.5). GATA4
is a key regulator of endoderm and mesoderm development in
the postgastrula embryo (Rossi et al., 2001). It also controls
the expression of genes critical for cardiomyogenesis while self-
regulating to eventually suppress its own expression as well (Rossi
et al., 2001). Over-expression of GATA4 in pluripotent P19 stem
cells or mouse embryonic stem (ES) cells can drive pluripotent
cells to a cardiac fate by increasing cardiac differentiation under
conditions known to favor a cardiac lineage (Grepin et al., 1997).
On a molecular level, GATA4 interacts with many transcrip-
tion factors to regulate the differentiation of progenitor cells.
MEF2C is a cofactor of GATA4 and plays a role in the devel-
opment of cardiac, skeletal, and smooth muscle (Morin et al.,
2000). In addition, GATA4 not only regulates the expression of
Nkx2.5 by enhancing activation (Akazawa and Komuro, 2005),
it also binds to Nkx2.5 causing a conformational change that
allows binding to the promoter of the atrial natriuretic factor
(ANF) which in turn stimulates alternative pathways to promote
cardiomyogenesis (Durocher et al., 1997). The activated tran-
scription factor Nkx2.5 also associates with Tbx5 to bind with
natriuretic peptide precursor type A (Nppa) to further stimulate
the generation of cardiac cells (Hiroi et al., 2001; Stennard and
Harvey, 2005).
Given that the acetylation of histone lysine residues by histone
acetyltransferases (HATs) increases the accessibility of chromatin
DNA for transcription factor binding (Wolffe, 1997; Chen and
Li, 2011), it is unsurprising that the p300 that contains an
intrinsic HAT activity also plays a major role in cardiac devel-
opment. By acting as a transcriptional coactivator of GATA4,
p300 increases the DNA binding capacity and stability of GATA4
(Dai and Markham, 2001; Kawamura et al., 2005). Genetic evi-
dence suggests that the primary reason for lethality in homozy-
gous p300 knockout mice stems from cardiac defects (Yao et al.,
1998). Spatiotemporal analysis of p300 expression demonstrates
widespread prevalence in the cardiac crescent and highlights a
crucial role in the spatial organization of the developing heart
(Chen et al., 2009).
Interestingly, MEF2C also interacts directly with p300 and
class II histone deacetylases (HDACs) in a mutually exclusive
manner on the same MEF2 domain (Sartorelli et al., 1997; Slepak
et al., 2001; Han et al., 2005). Consequently, when class II HDACs
are exported out of the nucleus in response to hypertrophic
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signals, MEF2C interacts with p300 to become fully transcrip-
tionally active and thereby activates downstream genes harboring
MEF2C binding sites. These studies strongly suggest that p300
may play an important role in progenitor cell commitment and
developmental morphogenesis within the fetal and hypertrophic
cardiac development program.
For over four decades, the anticonvulsant drug valproic acid
has been used worldwide in the treatment of epilepsy, migraine
pain, seizures, and bipolar disorder (Loscher, 1999; Johannessen
and Johannessen, 2003). Later, it was identified as a potent HDAC
inhibitor. Pertinent to this report, the marked capacity of valproic
acid to modulate chromatin and transcription has been exploited
to accelerate the induction of pluripotent stem cells from primary
human fibroblasts (Phiel et al., 2001; Kramer et al., 2003; Huangfu
et al., 2008). In this study, we examined the effect of valproic acid
on the specification of cardiac lineage and show that targeting the
HDAC activity within pluripotent stem cells enhances cardiac dif-
ferentiation. We also demonstrate that the direct involvement of
histone acetylation and p300 regulate GATA4 gene expression at
specific stages of cardiac differentiation, highlighting the precise
timing to enable the rational engineering of a ready cell source for
cardiac repair.
RESULTS
SMALL MOLECULE INDUCERS IN CARDIAC DIFFERENTIATION
To study the molecular regulation of cellular signaling and chro-
matin modification on cardiac differentiation, we used the P19
pluripotent stem cell model in our initial studies. Previous
studies have reported that treatment with 0.5–1% dimethyl-
sulfoxide (DMSO) induces the differentiation of P19 cells into
cardiac myocytes (Skerjanc, 1999). Consistent with these reports,
0.8% DMSO converted about 18% of cells into cardiomyocytes
as shown by quantitative microscopic analysis of the expres-
sion of cardiac troponin T (cTnT) and myosin heavy chain
(Figures 1A,B).
To delineate the role of histone acetylation in cardiomyogene-
sis, we also targeted HDAC activity with an inhibitor approach
as a means of increasing histone acetylation. To this end, val-
proic acid was used and different concentrations were tested
for its capacity to induce cardiac differentiation. As shown in
Figures 1A,B, about 11% of cells differentiated into cardiomy-
ocytes following valproic acid treatment similar to DMSO induc-
tion. In addition, valproic acid enhanced GATA4 gene expression
as revealed by the Western analysis (Figure 1C). These findings
are consistent with previous reports that HDAC over-expression
inhibits the development of cardiomyocytes by down-regulating
GATA4 and Nkx2.5 gene expression (Kawamura et al., 2005;
Karamboulas et al., 2006; Liu et al., 2009).
Interestingly, both DMSO and valproic acid also increased the
level of global histone H3 acetylation as revealed by the Western
analysis (Figure 1C). More importantly, they increased the associ-
ation of transcriptional coactivator p300 to the GATA4 promoter
when compared to the undifferentiated cells as shown by a real-
time PCR based chromatin immunoprecipitation (ChIP) analysis
(Figure 1D). Thus, enhancing histone acetylation and activating
gene expression by targeting HDAC activities represent promising
course of modulating stem cell fate decisions.
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FIGURE 1 | Valproic acid-enhanced cardiac differentiation. (A) P19 stem
cells were treated with DMSO or increasing concentrations of valproic acid
(VPA 0.5, 1, 2mM) during EB formation, maintained in the tissue culture
dishes for 3 additional days without treatments, and then stained for
myosin heavy chain and cTnT. Quantification is presented as fractions of
cells differentiated into cardiomyocytes relative to the total cell populations.
Error bars represent the standard deviations of three independent
experiments. (B) Shown are the representative microscopy images of the
cells stained for cTnT (green). Hoechst was used to stain the DNA (blue)
concomitantly (scale bars = 50μm). (C) Western analysis of GATA4 protein
expression and the levels of global H3 acetylation. The blots were then
stripped and reprobed for β-tubulin as loading controls. Undifferentiated
cells were included as a negative control. Shown are the cropped blot
images representing indicated protein. (D) Occupancy of p300 at the
GATA4 promoter (GATApro) and a control locus (GATActl) were examined by
a real-time PCR based ChIP analysis. Quantification is presented as the fold
variations of undifferentiated control.
HAT ACTIVITY AND CARDIAC DIFFERENTIATION
To determine the molecular basis for p300 involvement in early
cardiac differentiation, we used curcumin, a cell permeable com-
pound from curcuma longa rhizome, which inhibits the HAT
activity of p300 (Balasubramanyam et al., 2004). We have pre-
viously optimized the concentrations of curcumin treatments in
P19 cell differentiation (Francetic et al., 2012; Hamed et al., 2013)
and used 10μM curcumin in cardiac differentiation since it does
not exhibit apparent toxicity to the differentiating cells, while still
inhibiting about 40% of p300 HAT activity as determined by a
HAT assay (Francetic et al., 2012).
We first grew the ES cells as hanging drops for 2 days and as
suspension culture for 4 additional days to form embryoid bod-
ies (EBs). The EBs were then maintained on coverslips for 4 days
during cardiomyocyte development. Curcumin was administered
either during the early (day 0–2), middle (day 2–4), or late (day
4–6) stage of EB formation. Quantitative microscopic analysis of
cTnT and myosin heavy chain staining demonstrated that cur-
cumin treatment in the early stage led to a significant reduction in
cardiac differentiation, by about 60% (Figures 2A,B). However,
the inhibitory effect of curcumin progressively reduced when it
was administered in later stages of EB formation (Figures 2A,B).
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FIGURE 2 | Effects of curcumin on the differentiation of ES cells into
cardiomyocytes. (A) ES cells were grown in hanging drops for 2 days and
in suspension for 4 additional days to form the EBs. Treatment with
curcumin (10μM) was for days 0–2 (E), days 2–4 (M), or days 4–6 (L). The
cells were then maintained on cover slips for another 4 days to allow for the
development of cardiomyocytes. Quantification is presented as the
percentage of cells positive for cTnT and myosin heavy chain (MyHC),
respectively. Error bars represent the standard deviations of three
independent experiments (∗p < 0.05). (B) Shown are the representative
images of untreated cells stained for cTnT or myosin heavy chain (green) on
day 10 of differentiation. Hoechst was used to stain the DNA (blue)
concomitantly (scale bars = 50μm). (C) Western analysis of GATA4 protein
expression and the levels of global H3 acetylation. The blots were then
stripped and reprobed for β-tubulin as loading controls. Undifferentiated ES
cells and were used as the negative control. Shown are the cropped blot
images representing indicated protein.
The expression of GATA4 was similarly impaired by early cur-
cumin treatment and appeared to associate with a decrease in
global histone H3 acetylation (Figure 2C). Treatment in later
stage of differentiation did not negatively influence the levels of
GATA 4 protein by day 10 of differentiation (Figure 2C).
We also applied curcumin to the P19 differentiation system.
Treatment with curcumin during P19 EB formation inhibited
about 95% of DMSO-induced cardiomyogenesis (Figures 3A–C).
Early curcumin treatment (days 0–2) inhibited about 94%
of cardiomyogenesis, whereas the late treatment (day 2–4)
inhibited about 25% (Figures 3D,E). GATA4 and Tbx5 tran-
scripts increased about 130- and 75-fold respectively on day 4 fol-
lowing DMSO induction, while MEF2C and Nkx2.5 transcripts
increased about 30- and 80-fold respectively on day 7 (Figure 3F).
Early curcumin treatment prevented DMSO-enhanced GATA4,
Tbx5, MEF2C, and Nkx2.5 transcripts (Figure 3F). However,
administration of curcumin in later stage did not affect the lev-
els of GATA4, Tbx5, and MEF2C transcripts, but decreased the
Nkx2.5 transcripts, by about 85%, on day 7 (Figure 3F).
Western analysis confirmed that levels of GATA4 protein
increased about 10- and 40-fold on days 4 and 7, respectively,
compared to undifferentiated cells (Figures 4A,B). Curcumin
treatment during day 0–2, but not day 2–4, attenuated GATA4
protein expression, suggesting the activation of GATA4 locus
occurs in the early stage of EB formation. MEF2C protein
increased about 5-fold on day 7 in DMSO-treated cells rela-
tive to the undifferentiated controls (Figures 4A,B). Interestingly,
this MEF2C up-regulation was also attenuated by the addi-
tion of curcumin during day 0–2, but not day 2–4, suggesting
that either the activation of the MEF2C locus occurs in early
stage of EB formation, or MEF2C protein expression critically
depends on cardiac muscle regulator GATA4 or the expression
of unidentified curcumin-sensitive factors. Similar to GATA4
and MEF2C, cTnT gene expression was attenuated by treat-
ment with curcumin during day 0–2 (Figures 4A,C). However,
the expression of cTnT protein was also significantly reduced
(by about 60%) following curcumin treatment in the later
stage (day 2–4), while GATA4 and MEF2C were not affected
(Figures 4A,C). Again, global H3 acetylation increased following
DMSO induction but reduced following the addition of curcumin
(Figures 4A,B).
Taken together, our data demonstrate that curcumin inhibits
the specification of cardiac lineage and the expression of cardiac
muscle regulators if administered in the early stages of cardiac
differentiation. Interestingly, curcumin treatment has little effect
on cardiac differentiation when administered after initiation of
gene cascades responsible for dictating a cardiac fate. These stud-
ies highlight the importance of timely activation of GATA4 gene
expression in mesoderm formation for cardiomyogenesis.
HISTONE ACETYLATION AND p300 OCCUPANCY AT THE GATA4
PROMOTER
We next determined the effects of curcumin on histone H3
acetylation during P19 cell differentiation to dissect its effects
on the GATA 4 promoter from known anti-inflammatory, anti-
oxidant, and anti-tumor properties (Balasubramanyam et al.,
2004; Chen et al., 2007). Cells were differentiated with DMSO
and cotreated with curcumin during the first 2 days of EB forma-
tion. As shown by Western analysis, DMSO treatment increased
the cellular level of H3 acetylation by about 2-fold compared to
the undifferentiated control (Figures 5A,B). The addition of cur-
cumin decreased the DMSO-enhanced H3 acetylation by about
60% (Figures 5A,B).
ChIP analysis revealed that DMSO treatment augmented
H3 acetylation at the GATA4 promoter by about 2-fold
when compared to undifferentiated cells, while curcumin co-
treatment prevented the DMSO-augmented H3 acetylation
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FIGURE 3 | Effects of curcumin on the differentiation of P19 cells into
cardiomyocytes. (A) P19 stem cells were treated with DMSO during
EB formation. The addition of curcumin (10μM) was during the early
stage (days 0–2) or the late stage (days 2–4) of EB formation. The cells
were then maintained in the tissue culture dishes for 3 additional days
without any treatments, and stained for myosin heavy chain or cTnT
(green), and with Hoeschst for the nuclei (blue) (scale bars = 50μm).
(B) Quantification of the myosin heavy chain positive cells is expressed
as fractions of cardiomyocytes relative to the total cell populations. Error
bars are the standard deviations of five independent experiments
(∗∗p < 0.001). (C) Cells were treated with curcumin during EB formation
and quantified as the percentage of cardiomyocytes relative to the
DMSO control which is defined as 100%. Error bars are the standard
deviations of three independent experiments. (D,E) The administration of
curcumin was during the early stage (days 0–2) or the late stage (days
2–4) of EB formation. Quantification of the percentage of the myosin
heavy chain (MyHC) or cTnT positive cells is presented in relation to the
DMSO-alone control which is defined as 100%. Error bars are the
standard deviations of three independent experiments. (F) The mRNA
levels of GATA4, Tbx5, MEF2C, and Nkx2.5 were analyzed by real-time
RT-PCR using the same batch of cDNA, with GAPDH as internal
controls. Quantification is plotted as fold variations of the undifferentiated
controls. Error bars represent the standard deviations of the triplicates
from one representative experiment.
at the promoter (Figure 5C). While DMSO enriched p300
occupancy at the GATA4 promoter, early curcumin treat-
ment diminished the enrichment of p300 at the promoter
(Figure 5D). However, despite the occupancy of p300 being
largely reduced at the GATA4 promoter following curcumin
treatment, the level of cellular p300 protein was not affected
by the treatment (Figures 5A,E). Thus, histone acetylation
and p300 association are important for the early activation
of GATA4 gene expression at the early stages of cardiac
differentiation.
DISCUSSION
In this study, we used targeted small molecules to examine the
roles of p300 and histone acetylation in the regulation of GATA4
gene expression. We found that p300 is directly involved in
GATA4 gene regulation at the early stage of cardiac specification
and that valproic acid is an effective inducer to enhance histone
acetylation and cardiac specification (Figure 6).
DMSO is known to induce cardiomyogenesis in P19 stem
cells (Skerjanc, 1999), however, the exact mechanism of its action
remains largely unknown. It is thought that DMSO induces
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FIGURE 4 | Effects of curcumin on cardiac protein expression. (A) P19
stem cells were treated with DMSO and the addition of curcumin
(10μM) was during the early (days 0–2) or the late stage (days 2–4) of
EB formation. Western analysis was used to examine the levels of
GATA4, MEF2C, and cTnT protein, and global H3 acetylation. The blots
were then stripped and reprobed for β-tubulin as loading controls.
Undifferentiated cells were used as the negative control. Shown are the
cropped blot images representing indicated protein. (B) Quantification of
the Western blots is expressed as fold variations in relation to the
undifferentiated controls (mean ±SD, n = 3). (C) Quantification of cTnT
blots is plotted as percentages of the DMSO control (mean ±SD, n = 3,
**p < 0.005 relative to the DMSO control).
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FIGURE 5 | Occupancy of p300 at the GATA4 promoter at early stage of
differentiation. (A) P19 cells were differentiated with DMSO and
co-treatment of curcumin (10μM) was during the first 2 days of EB
formation. The cellular levels of H3 acetylation and p300 protein were
analyzed by Western blotting on day 4. The blots were then stripped and
reprobed for β-tubulin as loading controls. Undifferentiated cells were used as
the negative control. Shown are the cropped blot images representing
indicated protein. (B) Quantification of acetylated H3 blots is presented as
fold variations of the undifferentiated control (mean ± SD, n = 3). (C) The
levels of acetylated H3 at the GATA4 promoter were determined by the ChIP
analysis. Quantification is presented as fold variations of the undifferentiated
control. (D) Occupancy of p300 at the GATA4 promoter was examined in
parallel. (E) Quantification of the p300 Western blots is presented as fold
variations of the undifferentiated controls (mean ± SD, n = 3).
cardiac differentiation by triggering the release of intracellular
calcium stores without phosphoinositide breakdown (Morley and
Whitfield, 1993). Other studies have indicated the importance of
the Cx43 gap junctions and the oxytocin receptor system inmedi-
ating the effects of DMSO (Jasmin et al., 2010). We found that
DMSO-enhanced cardiac differentiation was associated with an
increase in histone acetylation and a concomitant enrichment of
p300 at the GATA4 promoter (Figure 1). Thus, our data indi-
cates a potential mechanism involving histone acetylation and
p300-dependent promoter activation in DMSO-mediated cardiac
differentiation.
Valproic acid is a popular clinical drug used to treat epilepsy,
migraine pain, seizures, and bipolar disorder (Loscher, 1999;
Johannessen and Johannessen, 2003). However, its exact mech-
anism of action has yet to be identified. Studies have shown that
it inhibits the activity of class I HDACs and induces the degra-
dation of class II HDACs (along with p300), thereby affecting
gene expression (Phiel et al., 2001; Kramer et al., 2003; Chen
et al., 2005). In this report, we demonstrate that valproic acid
induces cardiac differentiation and GATA4 gene expression which
coincides with p300 enrichments at the GATA4 promoter similar
to DMSO induction (Figure 1). From a mechanistic point, our
data highlights the importance of histone acetylation in cardiac
specification.
While the enrichment of p300 at the GATA4 promoter and
subsequent GATA4 gene expression is enhanced to a greater
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FIGURE 6 | Shown is the schematic presentation of sequential
activation of cardiac factors during the differentiation of stem cells
into cardiomyocytes. Pathway involved in linage specification step is
denoted with open gray arrows, whereas pathways involved in the
differentiation step are denoted with open green arrows.
degree by valproic acid than DMSO (Figures 1C,D), the abil-
ity of DMSO to promote cardiac differentiation is greater than
that of valproic acid (Figure 1A). This contrast could be related
to the fundamental differences between these inducers in modu-
lating the signaling pathways which may have differential impact
on cardiac gene program downstream of GATA4. Nevertheless,
treating ES and various induced pluripotent stem cells derived
frommurine fibroblasts with valproic acid increases the efficiency
of cardiomyogenesis regardless of the cell type by increasing
the expression of Nkx2.5, ANF, and cardiac contractile proteins
(Kaichi et al., 2010).
Curcumin inhibits p300 HAT activity (Balasubramanyam
et al., 2004). This inhibitory effect is mediated by its binding to
a non-active site region of p300 which results in a conforma-
tional change and thereby decreases the binding affinities of p300
to acetylCoA (uncompetitive inhibition) and histones (compet-
itive inhibition). This process takes place by a Micheal reaction,
with the α and β unsaturated carbonyl side chains of curcumin
serving as the acceptors by forming a covalent bond with p300
(Marcu et al., 2006). The concentration used in our studies is the
concentration with effective inhibition of histone acetylation but
with minimal cell toxicity (Francetic et al., 2012; Hamed et al.,
2013) and we show that HAT activity in the early commitment
stage is crucial for cardiac differentiation of ES and P19 cells
(Figures 2–4).
The temporal influences of HAT activity were observed in both
ES and P19 cardiac differentiation. Early HAT inhibition impeded
gene expression of GATA4,MEF2C, TBx5, andNkx2.5 (Figures 3,
4). These findings suggest that the MEF2C locus may be activated
during the early stage of cardiac commitment or that its activation
depends on GATA4 or other factors affected directly or indirectly
by the HAT activity. The sequential activation cardiac factors
during cardiac differentiation is well documented (Figure 6). It
is known that MEF2C is a cofactor of GATA4 and plays a role
in cardiac, skeletal, and smooth muscle differentiation (Morin
et al., 2000). GATA4 also regulates the expression of the Nkx2.5
by activation of its enhancer in combination with SMAD pro-
tein (Akazawa and Komuro, 2005). Nonetheless, HAT inhibition
in the late stage of differentiation does not affect GATA4, Tbx5,
and MEF2C activation, despite Nkx2.5 gene expression being
markedly reduced (Figure 3). Taken together, our data indicate
that HAT has a temporal involvement in the early commitment
stage to the cardiac lineage, in the activation of cardiac muscle
regulators and in the synthesis of filament proteins at the later
stages of differentiation.
We attempted to elucidate the molecular mechanisms under-
lying the early commitment to the cardiac lineage by investi-
gating the association of p300 to the GATA4 promoter as well
as histone acetylation. Following induction with DMSO, p300
association and H3 acetylation increased at the GATA4 promoter
(Figures 5C,D). HAT inhibition impedes the association of p300
to the GATA4 promoter correlating with a decrease in H3 acetyla-
tion (Figures 5C,D). Our findings indicate that the HAT activity
is important for early H3 acetylation and the recruitment of p300
to the GATA4 promoter, in turn influencing the expression of the
GATA4 gene.
It is known that the proximal GATA4 promoter harbors an
Nkx2.5 binding site which is important for GATA4 gene expres-
sion at the early stages of cardiomyogenesis (Riazi et al., 2009).
A recent genome-wide study of cardiac transcription markers has
shown that p300 interacts with Nkx2.5 and SRF, and that GATA4
coprecipitates with Nkx2.5 (He et al., 2011). Therefore, it is pos-
sible that p300 is recruited to the GATA4 promoter by Nkx2.5
to influence the expression of GATA4, the downstream cascade
of the cardiac regulators, and the eventual synthesis of filament
proteins at the later stages of cardiac differentiation.
Aside from the role of p300 in normal embryonic develop-
ment, HAT upregulation is also associated with hypertrophy by
reactivating and facilitating the fetal gene program in the adult
heart. Transgene-mediated p300 expression in the adult mouse
heart has been shown to result in hypertrophy and heart fail-
ure (Yanazume et al., 2003). The p300 acetylates regulators such
as GATA4, Nkx2.5, and MADS box protein, thereby enhancing
their activity to facilitate the activation of the cardiac gene pro-
gram (Sartorelli et al., 1997; Kakita et al., 1999; Dai andMarkham,
2001; Slepak et al., 2001). Curcumin treatment impedes the acety-
lation of GATA4 by p300 to hinder their interaction and disrupts
the downstream fetal gene program in adult murine cardiac tis-
sue subjected to hypertensive and hypoxic injury to significantly
improve heart failure outcomes (Morimoto et al., 2008). The
current work builds on these studies to indicate the critical time-
dependent role that p300 plays in cardiomyogenesis which may
have important implications in the activated fetal gene program
within stressed adult cardiac tissue.
MATERIALS AND METHODS
CELL CULTURE AND DIFFERENTIATION
P19 cells (ATCC) were maintained in Minimum Essential
Medium α (Invitrogen) supplemented with 5% fetal bovine
serum and 5% donor bovine serum (Multicell Wisent) at 37◦C
with 5% CO2. Differentiation was initiated by growing the
cells in Petri dishes in the presence of 0.8% of DMSO (Sigma-
Aldrich) or different concentrations of valproic acid (Sigma-
Aldrich), dissolved in autoclaved H2O. The EBs were then
cultured in tissue culture dishes for 3 days. ES cells (ATCC)
were maintained in the undifferentiated stage in Dulbecco’s
Modified Eagle Medium (Invitrogen) supplemented with 15%
fetal bovine serum (Multicell Wisent), 1% non-essential amino
acids (Gibco), β-mercaptoethanol and Leukemia Inhibitory
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Factor (LIF, Chemicon). For differentiation, the cells were grown
in the absence of LIF as hanging drops for 2 days, in suspension
for 4 additional days, and then cultured in tissue culture dishes.
Curcumin was purchased from Sigma and dissolved in ethanol for
use in treatments.
IMMUNOFLUORESCENCE MICROSCOPY
Cells were differentiated as indicated. After attaching to 0.1%
gelatin coated coverslips, the cells were fixed with ice cold
methanol, air-dried at room temperature and rehydrated in
PBS. The cells were then incubated with primary antibody at
4◦C overnight, with the secondary antibody Alexa Flor® 488
(Invitrogen) for 2 h, and with 0.1μg/ml Hoechst (Molecular
Probes) for 5min for nuclear staining. The cells were washed
with PBS in between each incubation, and washed before being
set on the slides with 10% glycerol(Chen et al., 2004). Following
the staining, the coverslips were visualized using Axiovert
200M microscope (Zeiss), AxioCam HRM camera (Zeiss) and
AxioVision Rel 4.6 software (Zeiss) (St-Germain et al., 2008).
For each coverslip, about 100 fields of view were analyzed and
the efficacies of differentiation were estimated based on cells
positively stained for cardiac markers cTnT or myosin heavy
chain in relation to the total cell population determined by
nuclear Hoechst staining. Student t-tests were used for statistical
analysis. Antibody for myosin heavy chain was from MF20
hybridoma and antibody for cTnT was from Abcam.
WESTERN ANALYSIS
The cells were lysed in whole cell extract buffer (10 % glyc-
erol, 50mM Tris-HCl pH 7.6, 400mMNaCl, 5mM EDTA, 1mM
DTT, 1mM PMSF, 1 % NP-40). Protein concentration was deter-
mined by using a Bio-Rad Protein Assay Dye Reagent (Bio-Rad)
and Multiscan Spectrum photospectrometer (Thermo). Equal
amounts of protein were separated on SDS-polyacrylamide gel
and transferred onto Immun-Blot PVDF membrane (Bio-Rad),
probed with specific antibodies and visualized using Western
Lightning™ Chemiluminescence reagents (Hamed et al., 2013).
The protein bands were quantified using Scion Image software
(Scion Corporation). The antibodies for p300, GATA4, and H3Ac
were from Santa Cruz Biotechnology. β-tubulin antibody was
described previously (Le May et al., 2011).
REAL-TIME RT-PCR ANALYSIS
The total RNA was isolated by using RNeasy Mini kit (Qiagen).
Multiskan Spectrum spectrophotometer (Thermo) was used to
determine the concentrations and the quality of the RNA (Chen
et al., 2010). Equal amounts of RNA were used in reverse tran-
scription with High Capacity cDNA Archive Kit—Multiscribe
Reverse Transcriptase (Applied Biosystems). Quantitative real-
time PCR amplification was carried out by using the Applied
Biosystems 7500 Fast Real-Time PCR System. The amount of
targets, normalized to the GAPDH endogenous reference and
relative to calibrator control is calculated using the arithmetic for-
mula 2−CT. The GATA4, Nkx2.5 and Tbx5 primer have been
described previously (Li et al., 2013). The primers for MEF2C are
the following:
MEF2C fwd- TCAGTTGGGAGACCGTACCAC
MEF2C rev- CCATCGTAGGAACTGCTACAG C
CHROMATIN IMMUNOPRECIPITATION
The P19 EBs were crosslinked with 1% formaldehyde and
lysed using ChIP Lysis Buffer (50mM Tris-HCl pH 8.0, 10mM
EDTA pH 8.0, 1%SDS, 1X protease inhibitors, 1mM DTT,
1mM PMSF), and then sonicated with the Bioruptor system
(Diagenode). The required amount of chromatin was diluted in
ChIP Dilution Buffer (20mM Tris-HCl pH8.0, 150mM NaCl,
2mM EDTA, 1% Triton X-100, 1x Protease inhibitors) and incu-
bated with the indicated antibodies overnight at 4◦C. Anti-IgG
serum was used as a negative control. The chromatin-antibody
complexes were pulled down by incubation with Dynabeads
Protein A (Invitrogen) for 2 h. The beads were then washed and
processed as previously described (Le May and Li, 2013). Purified
DNA targets were quantified by Real-time PCR. The fold increase
was determined with respect to the undifferentiated control, with
input chromatin DNA used as an internal control. Antibodies for
p300 and acetylated H3 were from Santa Cruz Biotechnology. The
GATA4 primers have been described previously (Voronova et al.,
2012).
Primers for GATA4 control:
Fwd-GAGCTGGTACCTGGCCTT C
Rev- GCTCTGCTGAAATCACTCTGA
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